ASH 2024 Summary: Myeloma Highlights and Impact on Practice

2024 ASH Annual Meeting Insights Hub

H. Hashmi

ASH 2024 Review: Key Multiple Myeloma Abstracts

Cleveland Clinic Taussig Cancer Institute

N. Callander

ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implicati…

2024 ASH Annual Meeting Insights Hub

S. Al Hadidi

Debate: Using BCMA CAR-T in Early vs Late Line R/R MM Treatment

Louisville Hematology Highlights

K. Patel, S. Usmani

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

Transition of Care for Bispecific Antibodies in RRMM: Closing the Ga…

Cleveland Clinic Taussig Cancer Institute

S. Mazzoni

Real-World Characteristics and Outcomes in Patients With RRMM Receiv…

Adeel Khan

CAR-T Strategies and Clinical Considerations for R/R MM

Moffitt Cancer Center

K. Patel

Making Sense in R/R Myeloma: Guideline-Based Current Approaches

Saurabh Chhabra

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

Anti-BMCA Bispecific Antibodies - Independent Symposium at the 10th …

Springer Healthcare IME

S. Usmani

ASH 2024 Insights: Efficacy of Anti-BCMA CAR-T in Myeloma Patients P…

2024 ASH Annual Meeting Insights Hub

J. Waldschmidt

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Maria-Victoria Mateos

Multiple Myeloma: Hot Topics in 2024

Yale Cancer Center

S. Browning

Talquetamab as a Bridging Therapy to BCMA CAR-T in RRMM

2024 ASH Annual Meeting Insights Hub

B. Dhakal

Indefinite Treatment of Multiple Myeloma: Strategies for Frail Patie…

Shaji Kumar

Evaluating Infection Risk in CAR T-Cell Therapy and Bispecific Antib…

Meera Mohan

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael